

in touch

SPRING 2005

The Newsletter for the Friends of Fox Chase Cancer Center

INSIDE...

Wegs Support Breast Cancer Program 2

Fox Chase Establishes Hanks Chair 3

Road to Excellence . . 4

Fox Chase Earns Prestigious Accreditation 5

Researchers Identify Novel Target for Detecting Ovarian Cancer 6



Scientists Earn International Awards . 8

Fox Chase Celebrates Centennial 10

Fairmount Park Commission Approves Fox Chase Cancer Center Expansion Plan

In a move that reaffirms Philadelphia's commitment to world leadership in cancer research and treatment, the Fairmount Park Commission approved Fox Chase Cancer Center's plan to expand its Northeast Philadelphia campus by utilizing 19.4 acres in neighboring Burholme Park. The plan will create approximately 4,000 new jobs through a series of phased expansions over 20 years.



Artistic rendering of Fox Chase Cancer Center in 2025

The Fairmount Park Commission will lease the 19.4 acres to Fox Chase for 80 years and give the cancer center the option to renew the lease for two additional multi-year periods. In return, Fox Chase will pay the Commission \$2.25 million dollars over three years, plus a percentage of construction costs as new buildings are developed in the five-phase construction plan. The Commission expects to utilize 50 to 75 percent of the money from this agreement for maintenance and improvements in Burholme Park.

"We are grateful to the Fairmount Park Commission for its support of the plan to position Fox Chase as one of the premier cancer centers in the world," says Fox Chase president **Robert C. Young, M.D.** "Its decision represents the culmination of many hours of meetings and thoughtful discussions involving all of the stakeholders in this project, including our neighbors, local businesses, city officials and a great many

other interested citizens. The Commission took the time to hear all sides and it used this information to help craft a better plan that will benefit the Center and the community."

A component of the agreement calls for replacing the acreage utilized by Fox Chase in Burholme Park. The Fairmount Park Commission has identified the 15-acre parcel of land owned by Fox Chase at Laurel Avenue in Cheltenham Township as a possible replacement site. Fox Chase will maintain its administrative offices located at Laurel Avenue. The construction of the American Cancer Society's Hope Lodge on this property will move forward as planned. This facility will provide free accommodations for eligible adult cancer patients receiving treatment in the Philadelphia area.

continued on page 7

Wegs' Five Million Dollar Gift Funds Signature Breast Cancer Research Program

Fox Chase Cancer Center announces a \$5 million gift from Fox Chase Cancer Center board vice chairman **Kenneth E. Weg** and his wife, **Carol**—the largest single gift made by individuals in the Center's recent history. Their contribution funds the development of a signature breast cancer research program led by two of the nation's and the world's top breast cancer researchers—**Monica Morrow, M.D.**, and **V. Craig Jordan, OBE, Ph.D., D.Sc.**

Jordan, a pharmacologist known as the “father” of the breast cancer drug tamoxifen, and Morrow, an internationally recognized breast cancer surgeon, have joined Fox Chase's division of medical science. The husband and wife team had served on the faculty of Northwestern University and Northwestern Memorial Hospital in Chicago since 1993.

The Wegs' gift supports the signature breast cancer research program, which includes high-volume breast cancer clinics, research strengths in molecular pharmacology and biological chemistry, and the associated laboratory space and equipment.

Morrow became chair of surgical oncology at Fox Chase last August—one of just a few women in the nation to chair a surgery department. She holds the Center's G. Willing “Wing” Pepper Chair in Cancer Research.

Jordan joined Fox Chase in January as vice president and scientific director for the medical science division. He holds the new Alfred G. Knudson Jr. Chair in Cancer Research. Jordan's published studies of tamoxifen and other selective estrogen-receptor modulators—called “designer estrogens”—have made him one of the top 20 most-cited breast cancer researchers over the past decade.

“We are extraordinarily grateful to Carol and Ken Weg for making it possible to develop a strong breast cancer research program to attract two top cancer researchers to Fox Chase,” said Fox Chase president **Robert C. Young, M.D.** “As Fox Chase plans for a 20-year expansion, we cannot overlook the impact outstanding faculty members have on advancing cancer research. The additions of Drs. Morrow and Jordan will have a significant impact on breast cancer research today and in the future.”

Morrow has been an outstanding advocate in the effort to ensure that women receive appropriate, state-of-the-art treatment for breast cancer and she has worked to expand prevention options for women, Young added. Jordan was a major force in the development of tamoxifen in the 1970s and it has subsequently become vital for treating women with breast cancer.

“Just six years ago, tamoxifen was shown to reduce the risk of breast cancer by 40 percent among high-risk women,” Young continued. “Dr. Morrow was a principal investigator on that prevention trial. This illustrates how Dr. Jordan through his preclinical work and Dr. Morrow with her clinical research work together to accelerate the translation of research from the lab to treatment and prevention.”

This is the *fourth* major gift Carol and Ken Weg have provided Fox Chase. In 2002, the Wegs funded the Audrey Weg Schaus and Geoffrey Alan Weg Endowed Chair, held by Fox Chase senior vice president for medical science Robert F. Ozols, M.D., Ph.D. In 1998, they endowed Fox Chase's first chair in population science, the Carol and Kenneth E. Weg Chair in Human Genetics, held by Joseph R. Testa, Ph.D., senior member and director of the Human Genetics Program at Fox Chase. In 1995, they provided significant funding for Fox Chase's Facility for Molecular Diagnosis of Hematologic Cancers.

The Wegs also are members of the Fox Chase Benefactors' Society, which recognizes friends of the Center who have provided for the future growth of Fox

continued on page 6



From left are V. Craig Jordan, OBE, Ph.D., D.Sc., Monica Morrow, M.D., Carol Weg and Ken Weg.



Gerald E. Hanks, M.D. (left), was honored with an endowed chair in his name at Fox Chase Cancer Center. His successor, radiation oncology chairman Alan Pollack, M.D., Ph.D., is the first to hold the chair.

Fox Chase Establishes Hanks Chair in Radiation Oncology; Pollack Becomes First Chair Holder

Fox Chase Cancer Center announces the establishment of *The Gerald E. Hanks Endowed Chair in Radiation Oncology*. Endowed for \$1.5 million, the new chair honors **Gerald E. Hanks, M.D.**, who served as Fox Chase's chairman of radiation oncology from 1985 until he retired in 2001.

Alan Pollack, M.D., Ph.D., who succeeded Hanks as chairman, has been named the first holder of the Hanks Chair. Contributions from Fox Chase faculty, staff, grateful patients of Hanks and friends of Fox Chase provide support for this new endowment.

Fox Chase colleagues and patients honored Hanks at a special tea this April when he made a return visit from California along with wife, **Barbara Fowble, M.D.**, who served as clinical director of radiation oncology at Fox Chase until 2001. Major contributors to the endowed chair also recognized Hanks at a special dinner.

"The Hanks Chair in Radiation Oncology is a lasting legacy to honor Dr. Hanks' innovative contributions in the treatment of prostate cancer as well as his genuine compassion towards

his patients," said **Robert C. Young, M.D.**, president of Fox Chase Cancer Center.

"When he came, Dr. Hanks had a vision for where he wanted to take the department," Young continued. "He proved the significance of radiation oncology in cancer treatment by leading multiple studies setting the benchmark for treatment. Under his leadership, Fox Chase developed a world-class radiation oncology program.

"As the Center continues to expand, it is fitting that we pay special tribute to an outstanding clinician who has contributed significantly to making Fox Chase Cancer Center what it is today. This chair will provide support for the detection, treatment and prevention of cancer while fostering creative science in radiation oncology well into this new century."

Having published more than 300 papers on prostate cancer, Hanks is recognized worldwide for his expertise in the field. He pioneered the use of three-dimensional, conformal radiation therapy (3D-CRT), which shapes the radiation beam to conform to the shape of the tumor. This approach

eradicates cancer cells while sparing nearby healthy cells and reducing the side effects of traditional treatment. Fox Chase initiated the 3D-CRT program in 1988. First used for prostate cancer, this therapy has become routine for many cancer sites and is now used by hospitals around the world.

In addition to pioneering new therapeutic techniques, Hanks was instrumental in establishing guidelines and new standards for quality of care. A leading authority on quality assurance in radiation oncology, he has been a principal investigator for national Patterns of Care Studies, which monitor radiation therapy nationwide.

Hanks established the Prostate Cancer Assessment Program at Fox Chase in 1996 for men at high risk of prostate cancer. It offers not only screening but also education about risk factors and how to reduce them, genetic counseling and the opportunity to take part in prevention-oriented research.

Like Hanks, Pollack is an internationally recognized expert in prostate cancer and other genitourinary cancers. He came to Fox Chase in 2001 from the

University of Texas - M. D. Anderson Cancer Center, where he headed the genitourinary section of the radiation oncology department and served as associate medical director of the genitourinary treatment center.

"Dr. Hanks has been dedicated to the advancement of medicine through research," said Pollack. "These funds will allow us to expand our fellowship program, which will have a significant impact on the department's research objectives.

"The department of radiation oncology attracts fellows interested in research in physics, radiobiology and clinical radiation oncology. The Hanks Chair will help support clinical and research fellows who spend a year or more in the department, providing a great opportunity to broaden our training efforts and significantly contribute to the field of radiation oncology in Dr. Hanks' name."

Under Pollack's leadership, Fox Chase became the first center in the Delaware Valley to treat prostate cancer patients regularly with intensity-modulated

continued on page 6

The Road to Excellence: Fox Chase Nurses Earn Magnet Re-Designation

Whether passing through the Hospital of Fox Chase Cancer Center as an employee, patient or visitor, your heart can't help but be warmed by the smiling faces of nurses. Scattered in various clinic areas, inpatient and outpatient units, operating rooms and administrative offices, each member of the nursing department helps create an uplifting and loving atmosphere. *Excellence* best sums up what the department stands for, strives for and provides all day, every day.

In 2000, the American Nurses Credentialing Center (ANCC) of the American Nurses Association recognized the Fox Chase department of nursing with Magnet designation, the gold standard of nursing care. Fox Chase became the *first specialty hospital* and the *first cancer center* in the nation as well as *Pennsylvania's first hospital* to receive Magnet status.

This past August, Fox Chase achieved re-designation as a Magnet facility. "Receiving Magnet recognition for another four years highlights the commitment of our staff to continually meet the needs of our

patients, physically and emotionally, in the best way possible," says **Anne Jadwin, R.N., M.S.N., A.O.C.N., C.N.A.**, director of nursing services.

Only 120 hospitals of more than 6,000 in the country have been deemed Magnet facilities since the first award was given in 1995. According to the ANCC, independently-sponsored research shows that Magnet-designated facilities consistently outperform non-magnet organizations, deliver better patient outcomes, have shorter lengths of patient stay and have lower patient mortality rates.

Holding such status, according to nursing career specialist **Maureen "Mickey" Mullin, R.N., B.S.N., O.C.N.**, helps recruit high-quality nurses to our institution as well as retain the nurses we already employ. "Magnet equals nursing excellence," she says. "Because our outstanding reputation is validated by the ANCC, we are able to recruit and retain the best nurses."

According to the ANCC, a hospital must re-apply at the end of its four-year designation to maintain Magnet status.



Nurses Carol Cherry (from left), Anne Jadwin and Nancy Barton proudly show Fox Chase Cancer Center's Magnet award and plaque after the Fox Chase nursing department earned re-designation.

Jadwin spearheaded the re-application process at Fox Chase—all two years of it.

The Second Time Around

Unlike the initial designation, re-application had to focus on the growth of the institution and include specific proof that Fox Chase was still Magnet-worthy. Since its first Magnet award in 2000, Fox Chase also has provided annual updates to the ANCC.

"We wanted to do some things differently the second time around," explains **Joanne Hambleton, R.N., M.S.N., O.C.N., C.N.A.**, vice president of nursing and patient services. "The re-application process presented an opportunity to invite nurses from every area of the hospital to participate and learn the significance of such an award."

Hambleton and Jadwin recruited roughly 25 nurses, who played key roles in the re-application process.

Intense and Immense

According to Hambleton, "intense" and "immense" are the only two words to describe the process. A steering committee was formed in 2002 to decipher the 64 core standards required in the application as well as to analyze the 14 "Forces of Magnetism" and Magnet hospital best practices. The steering committee met quarterly at first. Within a year, committee members held daylong monthly meetings. Members included nursing administrators, unit managers, staff nurses and clinical nurse specialists.

continued on page 9



Fox Chase Earns Prestigious Accreditation for Human Research Protection

Fox Chase Cancer Center has received full accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). Fox Chase is only the *second cancer center in the country and the first hospital in Pennsylvania, New Jersey and Delaware* to achieve such status.

AAHRPP accreditation recognizes institutions that meet and, in some areas, surpass state and federal laws on the oversight of human research, including clinical trials. Accreditation involves a rigorous review of an institution's research policies and practices, followed by a site visit from AAHRPP reviewers,

who are experts in human research protections. The process ensures that the institution is doing everything possible to protect people who are participating in clinical trials.

"This accreditation demonstrates Fox Chase's commitment to understanding the causes of cancer and to discovering better treatments of cancer while offering the highest level of protection for our patients and volunteers who participate in clinical research," said **W. Thomas London, M.D.**, chair of the Institutional Review Board at Fox Chase.

The Office for Human Research Protections and the

U.S. Food and Drug Administration require that all clinical trials be reviewed in depth by the hospital's Institutional Review Board, or IRB. If approved, the study must be re-reviewed on a regular basis.

The IRB also is charged with reviewing and approving the informed-consent forms, questionnaires and any materials used to recruit participants into studies. At Fox Chase, the IRB includes physicians, nurses, scientists, pharmacists, behavioral researchers, administrative and legal professionals, clergy and other community members.

"The Fox Chase IRB members are responsible for reviewing every single study that is proposed at Fox Chase involving human subjects or human tissue," explained **Susan J. Niskey**, associate administrator at Fox Chase and fellow of the

American College of Healthcare Executives (FACHE). "Our IRB members take their job very seriously. They ask hard questions and probe both the medical necessity and safety of each trial. Without a doubt, the safety of our patients and volunteers is the IRB's first priority."

Only 20 institutions nationwide have received accreditation since the AAHRPP was launched in 2001. For more information, visit www.aahrpp.org.



Many patients and their family members write to Fox Chase Cancer Center staff to express gratitude and appreciation for care. Following are excerpts from letters written by one patient's wife.

Dear Doctor Langer,

I knew there was going to be something different about you from the first moment we met because you came bursting through the door, very late, a red tie with children printed all over it flapping over your shoulder. What I didn't know then was how very special you were going to be in your treatment of my husband's disease and in your treatment of us as people. From the first moment, we trusted you because you disarmed us with your intelligence and warmth. Everything that followed confirmed that you are a doctor who really cares about people and who goes out of his way for them....

My husband faced The Door knowing that all had been done that could have been done. Thanks to you. I hope that the next time you enter a room, tie flapping and late, your patients realize you are a doctor worth waiting for. You are.

Corey J. Langer, M.D., is director of thoracic and head & neck medical oncology at Fox Chase Cancer Center.

Dear Kristen,

It is impossible to thank Dr. Langer for all he did for us without also thanking you... You just had a way of turning up at the precise moment you were needed, your usual good judgment at the ready.

I respect that you love your job. You never told me you do, but it shows in the way you treat everyone around you. I've respected you as a person since the first time you went and got answers to every single question we asked you—the first day we met—and you didn't even roll your eyes! (I would have)....

Looking back over the many nice things you did for us, I wish I had complimented you more frequently and more promptly. Heaven knows you deserve all the good words. Thanks for everything.

Kristen Kreamer, R.N., M.S.N., A.O.C.N., is nurse practitioner of ambulatory care at Fox Chase Cancer Center.

Wegs, continued from page 2

Chase in their wills or other deferred, planned gifts.

“We are committed to helping Fox Chase in its fight against cancer,” said Ken Weg. “Like the leading researchers at Fox Chase and around the world, Carol and I believe the

best way to make progress against cancer is with a combined clinical and laboratory research effort.”

With more than 33 years of experience in the pharmaceutical industry, Ken Weg retired in 2001 as vice chairman of Bristol-

Myers Squibb and became founder and chairman of Clearview Projects, Inc., a company based in Princeton, N.J., that provides strategic planning and transaction services to biopharmaceutical companies.

Fox Chase Establishes Hanks Chair in Radiation Oncology,

continued from page 3

Fox Chase Researchers Identify Novel Target for Detecting Ovarian Cancer in Blood

Fox Chase Cancer Center researchers have found a new way to detect ovarian cancer in the blood. The new method targets hypermethylation—one mechanism used by cancer cells to turn off genes that protect against tumor development.

“There is no other obvious body fluid available for ovarian cancer testing except the blood,” said **Mitchell Edelson, M.D.**, a gynecologic oncologist in the department of surgical oncology at Fox Chase and a co-author of the study. “In the past couple of years, we have seen detection attempts with proteomics (the study of proteins) and now with this method. It is encouraging to see so much activity regarding one of the most feared diseases for women.”

When tumor-suppressor genes are inactivated by hypermethylation, they cannot do their job, which allows cancer cells to develop. This work, reported in the journal *Cancer Research*, marks the first time hypermethylation has been examined for the detection of ovarian cancer.

Fox Chase molecular biologist **Paul Cairns, Ph.D.**, and his colleagues tested for hypermethylation of BRCA1 and RASSF1A, two genes strongly associated with ovarian cancer.

“In normal cells, BRCA1 and RASSF1A are unmethylated, meaning they are able to do their job,” explained Cairns. “We found these genes to be frequently hyper-

methylated in the blood and peritoneal fluid from patients with ovarian cancer, indicating the genes were effectively turned off.”

DNA from tumor samples, preoperative blood and peritoneal fluid (from the lining of the abdominal cavity) were obtained from 50 patients with ovarian or primary peritoneal cancer. These samples were compared with DNA from women without cancer.

Thirty-four of the 50 tumors (68 percent) showed hypermethylation of one or both genes. The remaining 16 tumor samples did not show hypermethylation for BRCA1 or RASSF1A but had hypermethylated forms of other tumor-suppressor genes, which provided targets for screening.

An identical pattern of gene hypermethylation was found in the matched blood DNA from 41 of 50 patients, including 13 of 17 cases of stage I disease. No hypermethylation was observed in the non-cancerous tissue, peritoneal fluid or blood from the samples of the healthy women in the control group.

“Hypermethylation is a common event in ovarian tumors and appears to happen relatively early because we found it in early-stage cancers,” said Edelson. “What’s encouraging about this research is that there were no false-positive results. A gene negative for hypermethylation in the tumor DNA was always negative in the matched serum or peritoneal fluid DNA.”



Paul Cairns, Ph.D.

The potential application of this finding could be significant because there is no reliable screening method available for ovarian cancer. Most women are diagnosed with late-stage disease after developing symptoms. The cure rate for women with advanced ovarian cancer is low, but doctors are often successful in treating early-stage disease.

“It would appear that hypermethylation is a very specific marker for this disease, and if confirmed in larger studies, methylation may be useful in ovarian cancer diagnosis,” said Cairns.

In earlier research, Cairns and his colleagues have demonstrated the ability to detect prostate and kidney cancer by targeting hypermethylation.

This research was supported by a National Cancer Institute grant to Fox Chase for a Specialized Program of Research Excellence in ovarian cancer, the Pennsylvania Department of Health Ovarian Cancer Program and the Ovarian Cancer Research Fund.

radiation therapy, or IMRT. The latest in a new generation of radiation treatment, IMRT allows radiation oncologists to administer powerful radiation doses to the tumor with extremely high precision while sparing surrounding healthy tissue.

Like 3D-CRT, IMRT has conformal capability, but IMRT allows the radiation beams to vary in intensity. The radiation can be maximized where the tumor is thickest and minimized when it is near healthy tissue. Patients experience fewer side effects with IMRT than with 3D-CRT.

By allowing the precise delivery of higher doses at each treatment session, IMRT also shortens treatment time for patients. In addition to prostate cancer, IMRT now is used to treat patients with breast cancer and selected other cancers.

Pollack received his Ph.D. in microbiology and immunology from the University of Miami in 1979 and served as a research health scientist and an assistant professor there until 1985. He earned his M.D. from the University of Miami School of Medicine in 1987 and interned at Miami’s Jackson Memorial Hospital. He completed his residency in radiation therapy at M. D. Anderson, where he joined the staff as an assistant professor in 1992 and became full professor in 1999.

Dragon Boat Teams Paddle to Success

They rallied. They paddled. They created a flood of enthusiasm and support for cancer research. The teams who participated in the third annual Philadelphia International Dragon Boat Festival raised more than \$407,000 to benefit Fox Chase Cancer Center.

Rooted in 2000 years of Chinese tradition, dragon boat racing has become the fastest-growing water sport in the world. Within the ornate boat is a crew of 20 paddlers, one drummer and a steersperson. The key lies in the team's ability to move in unison, combining strength and teamwork. A perfectly synchronized team will almost always beat a stronger, less coordinated team.

More than 100 teams raced down the Schuylkill River on Oct. 9 with each paddler raising \$100 in pledges in tribute to the 100th anniversary of the Hospital of Fox Chase Cancer Center. Tents along the river proudly displayed each team's name. Supporters in creative team T-shirts grilled food, picnicked and cheered along with other spectators. The day-long event featured multiple races of eight teams each.

Paddlers included community and business groups from Philadelphia and as far away as Toronto in Canada. Team members of all fitness levels and ages, from students to senior citizens, competed to finish the 500-meter racecourse.

Among them were six teams whose captains and crews were made up of Fox Chase Cancer Center employees and their friends and

family members: the *Fox Chase Cure Chasers*, *Foxdragons*, *Fox Chase RNs (River Nymphs)*, *Fox Chase We Are Family*, *Number Crunching Dragons* and *Rad-Onc Down Under*. These teams collectively raised more than \$47,500. Two additional boats with Fox Chase ties were *Positive Enrichment for Sisterhood*, led by Fox Chase reimbursement analyst **Toria Morin**, and **Team Binswanger**, headed by Fox Chase board member emeritus **Frank Binswanger**.

The 2004 event far exceeded the fundraising goal of \$300,000—more than doubling the 2003 total. It also marked the first time the Fox Chase web site was used for donations. Online donations accounted for approximately \$102,000. The new tool allowed Fox Chase to welcome many new friends with 75 percent of support for the event coming from first-time donors.

The fourth annual Philadelphia International Dragon Boat Festival is set for Saturday, October 1, 2005. Fox Chase Cancer Center is designated as the "featured charity" for the 2005 event.

For more information about the Philadelphia International Dragon Boat Festival, contact Carol Lee Lindner at 610-642-2333 and call Kathleen Price at Fox Chase at 215-214-1412 for pledging and sponsorship information. You can also log onto www.philadragonboatfestival.com or www.foxchasegiving.org/dragonboat.

Teams gathered to celebrate their Dragon Boat accomplishments at the post-festival celebration last November at Memorial Hall in Fairmount Park. The top fundraisers were recognized for their support.

Top Fundraising Teams (As of 10/22/04 deadline)

1. *The Paddling Peloton*
\$17,815.39
2. *West Dragon Fire II*
\$16,387
3. *St. Chris Baby Dragons - Baby A*
\$14,785

Highest Dollar Amount of Pledges Raised by an Individual

Rip Scott of Team Intensity from Main Line Health & Fitness
\$4,635

Highest Quantity of Pledge Donations Raised by an Individual

Theresa Ching of the Women Warriors team from Main Line Health & Fitness secured 73 individual pledges.

T-shirt Contest Winner
The Dragonflies won this distinction, receiving 190 votes for their team T-shirt.



SAVE THE DATE:

The 4th Annual
Philadelphia
International
Dragon Boat
Festival

Saturday,
October 1, 2005

Fox Chase Cancer
Center is designated as
the "Featured Charity"
for the 2005 event.

For more information:
[www.foxchasegiving.org/
dragonboat](http://www.foxchasegiving.org/dragonboat).

Ready, Willing and Able to Venture into New Waters

Crowd-cheering, paddling, drum-beating, competing. Come to the Philadelphia International Dragon Boat Festival to take in these sights and sounds. But take a closer look at the participants to get to the heart of the event.

Many teams united by dragon boat racing have gained not only experience with a new sport but also a sense of camaraderie and accomplishment. Look no further than team *Ready, Willing & Able*.

Team members, who won their first race at the third annual Festival in 2004, have achieved a great deal. Many have overcome drug and alcohol addictions and served time in prison. Through Ready, Willing & Able (RWA), the residential work-training program they belong to, they have taken steps to make a new start. Dragon boat racing has added to their momentum.

"It's just knowing I can do something in my life," says team member **Sylvester Brown**. "I'm sober and I'm not running away or mask-

ing myself anymore. I successfully completed the Dragon Boat Festival. I successfully obtained my driver's license. I have a new job. I'm in a new relationship. I am successful."

The name *Ready, Willing & Able* refers both to the work-training program, which opened in Philadelphia in 2002, and the dragon boat team. The men typically stay in the program for 10 to 12 months and graduate when they obtain full-time employment and permanent housing. Since its first appearance in the 2003 Dragon Boat Festival, the team has included various members of RWA as they have entered and graduated from the program.

Brown joined RWA in 2004 and competed in last year's Dragon Boat Festival for the first time. Connections made through dragon boating helped him land his job as a concierge at the Quadrangle, a senior citizens community in Haverford. Brown graduated from RWA in March.

continued on next page

Team Ready, Willing & Able with their coach, Carol Lee Lindner (far right), executive director of the Philadelphia Dragon Boat Festival.



Kathleen Price (left), director of special gifts at Fox Chase Cancer Center, poses with Debbie Bernstein, team captain of the #1 top fundraising team, the Paddling Peloton.



continued from previous page

“From Dragon Boat to job opportunities to new friendships,” says **Carol Lee Lindner**, the Festival’s founder and executive director, “so much good comes out of this event. It’s not just about the Festival itself.”

Lindner first met RWA members along the Schuylkill River a couple years ago. Severe weather conditions from Hurricane Isabel meant moving several boats, including the Festival’s two dragon boats and the double-hulled outrigger canoe used by the Challengers, from the river to Lloyd Hall. Lindner’s daughter, **Alexis**, who has Down syndrome, competes in the Dragon Boat Festival with the Challengers, a team of mentally challenged participants.

“When I got there,” Lindner remembers, “I saw the men in their blue uniforms already lifting the boats to safety. I was so impressed with how hard they worked and how carefully they handled the boats. I didn’t know who these men were, but I knew I had to recruit them to be part of the Festival.”

“I’m 55 years old, have lived in Philly all my life and had never been on the Schuylkill River,” Brown says. “So when Carol Lee showed an

interest in having us participate, I decided to give it a try.

“Our team was very disorganized the first week of practice,” Brown recalls. “We had to become cohesive and learn to work as a unit, not as individuals. At first, I didn’t think I’d complete it. I didn’t think I’d like it.”

Then, he experienced it. Practice, teamwork, race day.

“It was fantastic,” Brown says. “It’s a peaceful, exhilarating experience to be on the river during practice. It’s quiet on the river, yet we were surrounded by the city.”

“To be part of a team like this,” says Lindner, “It was wonderful to see the camaraderie develop, to see each teammate pulling for each other, encouraging each other.”

Brown shared race day with his children and grandchildren, who came to the Festival to cheer for him. With sobriety, he says, he has reconnected with family.

“I took so much from my children with my drinking, but I have a great relationship with them now. Being a part of the Dragon Boat Festival helped draw me even closer to my family.”

For Lindner, coaching RWA has brought many new friendships into her life. She keeps in

touch with many of the teammates through phone calls, letters and e-mails.

Several of the men also take juggling lessons with her and are learning to play handbells in the handbell choir at her church. Lindner has been involved in helping her teammates find jobs as they near graduation from RWA as well as look for apartments.

“We’ve become a real team,” she says. “This year, the same group will paddle again in the Festival. Many will do volunteer work, helping coach other teams and steer the boats.”

“Carol Lee brought something out in me I had never seen before,” Brown says. “I see it in other individuals in this facility. She does not judge me as an addict or as a failure. She nurtures by getting to know people. She helped me dig deeper inside myself.”

“Society has us so divided by class and social status that we actually don’t get a chance to see what a joy it is to have fellowship with people,” says **Michael Brooks**, a RWA teammate. “Our differences should be the thing that brings people closer together, to learn, encourage

and to just enjoy. It shouldn’t be to divide.”

“The Dragon Boat Festival is very inclusive and diverse,” Lindner points out. “That’s the beauty of dragon boat racing.”

Joining the Festival roster this fall will be some new teams, including a group from the Pennsylvania School for the Deaf and a team with blind paddlers.

Sylvester Brown, along with many RWA members, will return this year.

“We became known around the Festival for humming a song, which became our trademark,” he says. “But we knew that we really had bonded by the end of the day when, together, we hoisted Carol Lee on our shoulders. It’s not about winning or losing. It’s about participating.”

For more information about the Philadelphia International Dragon Boat Festival, contact Carol Lee Lindner at 610-642-2333 and call Kathleen Price at Fox Chase at 215-214-1412 for pledging and sponsorship information. You can also log onto www.philadragonboatfestival.com or www.foxchasegiving.org/dragonboat.



Sandra Weckesser (left), vice president for institutional advancement at Fox Chase Cancer Center, accepts a check from Carol Lee Lindner, founder and executive director of the Philadelphia International Dragon Boat Festival, in support of cancer research at Fox Chase.

Thank you to the sponsors of the 2004 Philadelphia International Dragon Boat Festival and to the many teams who supported Fox Chase Cancer Center through their participation and fundraising efforts.

2004 CORPORATE SPONSORS

ING
 Ortho Biotech
 Philadelphia Daily News
 Phillips' Fine Wines & Liquors
 PPL
 Sunoco
 The Philadelphia Inquirer
 Wyeth Pharmaceuticals



Rip Scott of Team Intensity from Main Line Health & Fitness holds up his framed print of Boat House Row as his team celebrates his accomplishment. Scott received the print for collecting the highest dollar amount of pledges by an individual.

Final Team Totals (Post 10.22.04 deadline)

Abington Friends A.F.S.	Frankford Friends Peaceful	MWN Dragonhearts	St. Chris Baby Dragons - Baby A
Pinafore\$3,456.00	Dragons\$1,847.00	Reach Out III\$8,105.00\$14,810.00
American Heritage FCU Patriots	Gerlad's Gang\$3,295.00	NJ Paddlecrackers\$2,334.00	St. Chris Baby Dragons - Baby B
.....\$1,870.00	Green Wooden Monkeys\$2,535.40	Number Crunching Dragons\$8,588.00
Beaton Family\$5,960.00	GSK\$279.86\$5,811.00	St. John Neumann Dragons
Big Red Dragons I ...\$6,295.00	Gung ho!\$6,561.00	Oar Derves\$2,855.00\$2,895.00
Big Red Dragons II ...\$3,055.00	Healthplex\$3,560.00	On the Waves to St. A ...\$110.00	St. Thomas Dragon Slayers
Bywood Buccaneers ...\$1,141.00	Heartbeats\$2,700.00	Paddle Power\$1,100.00\$6,803.00
Cadette Canoers\$250.00	Highland Park Paddle Pushers ..	Parkway Cruisers\$140.00	Sunoco Ultra Warriors \$1,445.00
Carpe Diem\$4,818.59\$3,139.00	Philadelphia Flying Phoenix	Team Binswanger ...\$5,553.00
Double Happiness ...\$2,480.00	Hillcrest Hurricanes ..\$2,558.00	Orange Team\$2,880.00	The Foxdragons\$6,249.00
Dragon Breath\$935.00	Huffer Puffers\$3,393.44	Philadelphia Flying Phoenix Red	The Paddling Peloton \$17,865.39
Dragon Ladies\$8,070.00	ING Lionhearted I ..\$6,030.00	Team\$833.00	The Stonehurst Hills Sea
Dragon Slayers\$5,343.00	ING Lionhearted II ..\$4,836.00	Philadelphia Police\$0.00	Stallions\$20.00
Dragonflies\$12,402.50	La Femme Force\$6,252.63	Philadelphia Youth Dragon Boat	Thorndale Rotary\$450.00
Drexel Dragons\$3,808.00	Last Dragons of Exponent\$400.00	Team\$426.00	Tombstone Raiders ..\$5,821.00
Drexel Moto Dragons \$1,238.00	Lightspeed\$5,655.00	Plumbers Union Local 690 ...	Tryin' Not To Sink ...\$6,255.25
Drexel Technical Inc.\$0.00	Main Line Health & Fitness -\$2,502.00	Turner Investment Partners
EwingCole Wave\$3,439.00	Team Intensity\$10,793.00	Positive Enrichment for\$3,955.00
Fairmount Park Commodores ..	Main Line Health & Fitness -	Sisterhood\$3,155.00	V-Span Vipers\$1,350.00
.....\$1,080.00	Women Warriors ...\$9,810.00	Rad-Onc Down Under\$11,236.00	Wei Li\$100.00
Fiserv LeMans Racers ...\$550.00	Medstaff\$295.00\$8,598.00	West Dragon Fire I ..\$11,896.00
Fox Chase Cure Chasers\$8,812.78	MWN Dragonhearts	Saint Joseph's Hawks ..\$4,035.77	West Dragon Fire II ..\$15,839.00
.....\$8,812.78	Reach Out I\$13,154.25	Savoy Goldoliers\$235.00	Wild Things\$12,152.00
Fox Chase RNs (River Nymphs)	MWN Dragonhearts	Sherry Maria I\$5,170.00	Wilmington Blue Dragons
.....\$9,324.00	Reach Out II\$9,508.00	Sherry Maria II\$2,345.00\$4,575.00
Fox Chase We Are Family\$6,146.00		Siemens Senmurv\$980.00	Wm. Penn Charter School\$3,648.00
		Snapdragons\$7,410.00	Wyeth Wyverns\$2,805.00
			Yao Shi\$12,368.00

Board of Associates Tops Annual Contribution

Andrea “Andi” Mitchell (left in photo), president of Fox Chase Cancer Center’s volunteer Board of Associates, presented a check for \$711,060 to Fox Chase president **Robert C. Young, M.D.** The annual contribution, designated for cancer research and patient care, represents the fundraising efforts for the past year by the Board of Associates, which raised \$28,000 more than the previous year.

The Board of Associates is a volunteer group with eight member organizations, representing more than 700 volunteers in the five-county Delaware Valley area and New Jersey who conduct fundraising and educational activities in support of Fox Chase. For information about volunteering, please call (215) 728-2441.



Expansion Plan, *continued from front page*



Fox Chase Cancer Center’s expansion plan is expected to proceed over a 20-year period and will add as many as 4,000 permanent new jobs and \$40 million in tax revenues to the city which is working to expand its workforce. Fox Chase’s expansion will include a new state-of-the-art hospital, an outpatient treatment center and cutting-edge research facilities.

The Center’s board of directors considered the Commission’s decision at its meeting March 29 and authorized planning to go forward on two patient care facilities to be constructed on the current Fox Chase campus. The \$70 million dollar construction projects were halted last fall until negotiations with the Fairmount Park Commission were completed. As part of this phase of expansion, Fox Chase plans to construct a parking garage on the newly acquired land.

The approved plan represents a compromise that significantly reduced the Burholme

Park acreage sought for the project—from 25 acres to 19.4 acres. Young explains the revisions: “Our plan reflects several thoughtful suggestions made by those impacted by our growth. For example, it was suggested that we build a parking facility underground to preserve more parkland and we plan to do that. It was suggested that we construct slightly higher buildings to preserve parkland and we can do that while respecting other neighbors who want our buildings significantly hidden by the canopy of trees. It also was suggested that we shift our entire footprint to the west to avoid using land where the playground currently exists and we have been able to do that as well.”

In February, the Fairmount Park Commission appointed a subcommittee to vet the revised plan and negotiate the final terms. The Fox Chase expansion plan leaves intact the Burholme Park playground, ballparks, sledding hill and Ryerss Museum. Instead, its primary focus is on land currently being used for commercial purposes (the golf driving range and batting cages), although the plan allows for this business to continue operating until such time as the land is actually needed for construction.

“Nearly the same amount of parkland actively used now will be available to the pub-

lic after our expansion,” Young explains. The revised plan makes more use of the passive area in the park. When combined with the amount of acreage currently fenced off and used for commercial purposes, the total of actively usable and available land will be within two acres of the actively used land now. “We are especially pleased that this agreement allows us to make a significant direct financial investment in Burholme Park.

“This plan will allow Fox Chase to create the research and treatment facilities that will be necessary to treat the more than 10,000 new patients who will need our help in the next decade,” Young says. “Cancer is primarily a disease of the aging. As our population grows older, demand for treatment will continue to rise dramatically. The demand for cancer care will explode in the next decade. We need to grow to handle this demand and this plan allows us to do so.”

Fox Chase was founded more than 100 years ago with the opening of the nation’s first cancer hospital in West Philadelphia. It moved to its current location in 1968. The 100-bed hospital remains one of the few facilities in the country devoted entirely to cancer care. Today, Fox Chase sees more than 6,500 new patients a year—a number that is expected to double by 2015.

Knudson Receives Kyoto Prize in Japan

It was a trip to the Land of the Rising Sun for one Fox Chase Cancer Center scientist whose work opened a new horizon in modern cancer genetics. Fox Chase Distinguished Scientist **Alfred G. Knudson, M.D., Ph.D.** (below, second from left), received the 2004 Kyoto Prize in basic science for his theory predicting the existence of tumor-suppressor genes. He traveled to Japan this past November for the Kyoto Prize Ceremony.

Considered among the world's leading awards for lifetime achievement, the Kyoto Prize, given by the Inamori Foundation since 1985, honors those who have "contributed significantly to mankind's betterment" in the fields of advanced technolo-

gy, basic sciences, and arts and philosophy. Founder Kazuo Inamori presented Knudson with the 20-karat gold Kyoto Prize Medal during prize ceremonies at Kyoto International Conference Hall. Along with the medal, Knudson also received a diploma and a gift of 50 million yen (about \$450,000).

Knudson also participated in the fourth annual Kyoto Laureate Symposium in March at San Diego State University; the University of California, San Diego; and the University of San Diego.

To read more about Dr. Knudson and the Kyoto Prize, log onto <http://www.fccc.edu/news/knudson/kyoto-prize.html>.



Retired Fox Chase Scientist Wins Nobel Prize

Irwin A. "Ernie" Rose, Ph.D. (left in photo), accepts the Nobel Medal from Sweden's **King Carl Gustaf XVI** during the Nobel Prize Ceremony in Stockholm, Sweden, this past December. Rose shares the 2004 Nobel Prize in chemistry with his two Israeli colleagues, **Aaron Ciechanover, Ph.D.**, and **Avram Hershko, Ph.D.**, for a series of biochemical studies on the breakdown of proteins within cells. Starting in the late 1970s, much of their joint work was done during a series of sabbatical leaves that Hershko and Ciechanover spent as visiting scientists in Rose's laboratory at Fox Chase Cancer Center. Hershko and Ciechanover are both scientists at Technion-Israel Institute of Technology in Haifa.

A senior member of Fox

Chase's division of basic science since 1963, Rose retired from Fox Chase in 1995. In 1997, he accepted a special appointment as emeritus researcher at the University of California at Irvine.

Rose returned to Fox Chase in the fall for a special symposium and tea in his honor. He was presented with a limited-edition "Centennial Rose" during a celebratory dinner at Philadelphia's National Constitution Center commemorating the centennial of the Hospital of Fox Chase Cancer Center. He also was recognized for his achievements by the City of Philadelphia with a Liberty Bell replica known as the "Key to the City" and a citation signed by Mayor John F. Street.

Charitable Gift Annuities

What would you think of a plan that enables you to make a significant gift to support research at Fox Chase Cancer Center while you increase your income and decrease your taxes?

Sound too good to be true?

It's true and it's simple to do. If you are age 65 or older, consider joining those who support Fox Chase through a charitable gift annuity.

A charitable gift annuity provides a fixed lifetime income stream in exchange for your gift to Fox Chase Cancer Center. Better yet, your annuity payments may be partially tax-free.

For more information or a sample illustration of how a charitable gift annuity might work for you, call Judith A. Lopacki, director of special gifts, at 215-728-4084.

We Goofed!

In the fall edition of In Touch listing our annual donors for 2003, we omitted the Bernard A. and Rebecca S. Bernard Foundation. The Bernard Foundation has been a loyal supporter of Fox Chase Cancer Center since 1980. The foundation trustees, Joan and Bill Bernard, Marlyn Bernstein and Estelle B. Solomon, represent the foundation on Fox Chase's President's Roundtable. The Bernard Foundation supported the establishment of the laboratory of Louis Weiner, M.D., Vice President for Translational Research and holder of the G. Morris Dorrance Jr. Endowed Chair. Look for the listing of the Bernard Foundation in the 2005 President's State of the Institution Letter coming soon.

Magnet Re-Designation,

continued from page 4

"I was somewhat intimidated and nervous about participating on the steering committee," says **Nicole Ewerth, R.N., O.C.N.**, a staff nurse on 1 Central. "I wondered what a staff nurse like myself had to contribute. I quickly realized that it was the staff nurses who were implementing a lot of the practices."

In January 2004, Jadwin sent the completed 12-inch-thick binder to the ANCC. Fox Chase nurses had spent almost six months writing the re-application materials it contained.

"I used to tell people the core grant application was tough," remarked Fox Chase president **Robert C. Young, M.D.**, about the cancer center support grant from the National Cancer Institute, "And it is. But the core grant is half the size of the Magnet application. This is another tremendous accomplishment for our nurses."

Appraisers from the ANCC arrived at Fox Chase several months after Jadwin submitted the application. Before their two-day visit, Jadwin identified "unit champions" and prepped selected nurses on what to expect from the visitors.

Highlights

Appraisers asked to meet with patients and employees on the second day of the site visit to better grasp the relationship and care given by Fox Chase nurses. "This is one of the most special parts of the whole process," Hambleton explains. "I cried



Fox Chase nurses celebrate earning Magnet re-designation for nursing excellence at a special tea in their honor.

when I saw the number of people who poured into the nursing education room to share their feelings. For many of us, that is what nursing is all about."

Mary Ann Michini, human resources director at Fox Chase, shared her special bond with the nurses. Michini's father passed away one and a half years ago after receiving treatment for multiple myeloma at Fox Chase. "My dad wasn't treated special for any other reason than other

patients are," she says. "That is just how nursing is done here."

In the Pain Management Center and Palliative Care Service, programs headed by vice chairman of medical oncology **Michael Levy, M.D., Ph.D.**, "the nurses are not just the 'magnets' but the girders upon which we build our interdisciplinary care plans. It is the nurses who directly give the care that is aimed at reducing the burden of cancer."

Fox Chase Cancer Center Marks Anniversary with Centennial Celebration

Fox Chase Cancer Center, the nation's *first* cancer hospital, celebrated its 100th anniversary with a Centennial Celebration this past November at the National Constitution Center in Philadelphia.

Fox Chase's roots go back to 1904 when a group of Philadelphia physicians and business leaders who believed that cancer could be a curable and possibly preventable disease chartered the American Oncologic Hospital in West Philadelphia. The founders chose "oncologic" from the Greek for tumor because people were so afraid to say the word "cancer" out loud.

The Hospital later relocated to the Fox Chase neighborhood in 1968. In 1974, it joined with the Institute for Cancer Research to form Fox Chase Cancer Center. Today, Fox Chase is one of the nation's leading comprehensive cancer centers, designated by the National Cancer Institute.

Donors, friends and employees joined in the dinner celebration. The evening began with the Heritage Reception, taking guests through 100 years of cancer progress with commemorative posters and other memorabilia.



Fox Chase board member G. Morris Dorrance Jr. (left) talks with Fox Chase vice chairman of surgical oncology and chief of thoracic surgical oncology Melvyn Goldberg, M.D.

Fox Chase Cancer Center honored internationally known scientist **Alfred G. Knudson Jr., M.D., Ph.D.**, with its Stanley P. Reimann Honor Award. Fox Chase also presented its first Centennial Awards to recognize contributions in the fight against cancer by Bristol-Myers Squibb Co. and Coaches vs. Cancer. The presentations took place at the National Constitution Center during the Centennial Celebration of the Hospital of Fox Chase Cancer Center.

Knudson, a Fox Chase Distinguished Scientist and senior advisor to Fox Chase president Robert C. Young, M.D., is the 11th recipient of the Reimann Honor Award. Established in 1974, the award commemorates the founder of the Fox Chase Institute for Cancer Research. In the 1920s, Stanley Reimann, M.D., a pathologist, was among the first to advocate the need for studying normal cell growth as a way of gaining insight into the uncontrolled growth of cancer. This approach ultimately changed the course of most laboratory research on cancer, leading to numerous landmark

Bristol-Myers Squibb chairman and CEO Peter Dolan (right) accepted a Centennial Award from Fox Chase president Robert C. Young, M.D., for the company's dedication to cancer treatment and research.



discoveries about normal cells and cancer-related changes.

first board chairman of the Center.

Knudson has been a senior member of the basic science division at Fox Chase since 1976, when he became director of the Institute for Cancer Research. A geneticist and physician, he is internationally recognized for his "two-hit" theory of cancer causation, which explained the relationship between hereditary and non-hereditary forms of cancer and predicted the existence of tumor-suppressor genes. His now-confirmed theory has advanced understanding of errors in the genetic program that turns normal cells into cancer cells.

Fox Chase president **Robert C. Young, M.D.**, presented the two Centennial Awards to recognize organizations and individuals who have made a dramatic impact in the area of cancer prevention, awareness, advocacy and education.

Coaches vs. Cancer received the Centennial Award for outstanding service by a volunteer organization to the cancer community. Coaches vs. Cancer is a joint program of the American Cancer Society and the National Association of Basketball Coaches to fight cancer, leveraging the strength and influence of the country's basketball coaches to reduce cancer risk, especially in young people, through education programs and to raise funds for the American Cancer Society.

Bristol-Myers Squibb Company earned the second Centennial Award for the company's dedication over the past 40 years to improving the care and treatment of those living with cancer and to advancing the cause of cancer research. Bristol-Myers Squibb chairman and CEO **Peter Dolan** accepted the award.



Fox Chase Distinguished Scientist Alfred G. Knudson Jr., M.D., Ph.D., (center) received the Reimann Honor Award at the Centennial Celebration. Joining him are University of Pennsylvania men's basketball head coach Fran Dunphy (left) and Saint Joseph's University men's basketball head coach Phil Martelli, who accepted a Centennial Award on behalf of Coaches vs. Cancer.



Joining a bicyclist at the National Constitution Center are Fox Chase board member Andrew L. Lewis IV (second from left), Fox Chase board member Sandi Mann, Board of Associates president Andi Mitchell and Suzanne Binswanger. Mann, Mitchell and Binswanger along with their husbands, Fred II, Clay and Frank Jr. served as co-chairs of the celebration.



Managing director of the Wilma Theater Lynn Landis (from left), Harvey Kimmel, friend of Fox Chase and President's Roundtable member, and Fox Chase board member Jane Pepper attended the Fox Chase Centennial Celebration preview reception, held at Meadowbrook Farm. The reception honored the Fox Chase Cancer Center President's Roundtable and Centennial sponsors. The President's Roundtable comprises the Centers most generous donors.



Fox Chase executive vice president and chief operating officer R. Donald Leedy (left) chats with Sandra and David Marshall, Fox Chase board member.



Fox Chase board member A.J. Gabriele (far right), who chairs the institutional advancement committee, and his wife, Barbara, helped celebrate 100 years of progress against cancer at the Centennial Celebration.



Three internationally recognized Fox Chase scientists (from left) 2004 Nobel laureate in chemistry Irwin A. "Ernie" Rose, Ph.D., 2004 Kyoto Prize winner Alfred G. Knudson Jr., M.D., Ph.D., and 1976 Nobel laureate in medicine Baruch Blumberg, M.D., Ph.D., have some lighthearted fun at the National Constitution Center, the site of Fox Chase Cancer Center's Centennial Celebration.



Fox Chase president Robert C. Young, M.D. (second from left), celebrates with the Zaslow brothers—from left, Arnold, Jerome and Spencer.

Non-Profit
Organization
U.S. POSTAGE
PAID
Philadelphia, PA
Permit No. 3187



333 Cortman Avenue | Philadelphia, Pennsylvania 19111
215 728 2745
www.fccc.edu

In Touch Volume 21, Number 1
Published by Fox Chase Cancer Center
1-888-FOX CHASE
www.fccc.edu
Robert C. Young, M.D.,
President
R. Donald Leedy
Executive Vice President
Sandra W. Weckesser, J.D.
Vice President, Institutional Advancement
Christine M. Wilson
Vice President, Communications
Karen Carter Mallet
Director, Public Affairs
Jill Horne
Writer & Editor
Kim Williams
Art Director
Randi Sargent
Graphic Artist
Karen Carter Mallet
Colleen Kirsch
Paul Cohen
Susan Tobin
Contributors

UPCOMING EVENTS

Garden Party & Country Buffet Sunday, June 12, 2005, 3 - 7 p.m.

Enjoy hors d'oeuvres, cocktails and dinner amidst the beauty of Elm Grove Estate, 5453 Old York Road, Buckingham, Pa. at this annual event, sponsored by the Bucks County Chapter

of the Board of Associates. The party also features live and silent auctions and a raffle. For reservations, call Jean Fowler at 215-297-0610.

Jill Marie Tulli Ride for the Cure Sunday, September 25, 2005 • Rain Date: Sunday, October 2, 2005 Registration and refreshments: 9 a.m. • Kickstands up: 10 a.m.

Rev up your engines and cruise scenic Pennsylvania roads for this fifth annual motorcycle ride, beginning and ending at Montgomeryville Cycle Center, Hatfield, Pa. The day includes lunch, prizes and raffle drawings.

Registration fee is \$15 each for riders and passengers (\$22 on the day of the ride.) Proceeds benefit research, education and treatment programs at Fox Chase. To register, call Linda Lowe at 215-728-2810.

4th Annual Philadelphia International Dragon Boat Festival Saturday, October 1, 2005 Schuylkill River-Kelly Drive-Fairmount Park

Catch the action on the river! This growing community event continues to fire up excitement as teams, spectators and volunteers come together for dragon boat racing. Fox Chase Cancer Center is designated as this year's "featured charity." See how you can get involved!

For more event information, call Carol Lee Linder at 610-642-2333. For pledging and sponsorship information, call Kathleen Price at 215-214-1412. You can also log onto www.philadragonboatfestival.com.

Advanta Tennis Championships October 30 through November 6, 2005

Love means a winning event as guests celebrate the Advanta Tennis Championships at a kickoff party on Sunday, October 30. Catch world-class tennis as the first match gets underway Monday, October 31 at the Pavilion at Villanova University. A special Fox Chase Night will take place Saturday,

November 5. Fox Chase Cancer Center is presenting sponsor and beneficiary of the Advanta Tennis Championships. For more information, contact Fox Chase's institutional advancement office at 215-728-2745 or log onto www.advantatennischampionships.com.

One World, One Quest Gala Sunday, November 13, 2005

Join in the fight against cancer as the American Association for Cancer Research (AACR) co-sponsors a star-studded gala with The V Foundation for Cancer Research. Olympic Gold Medalist, ESPN broadcaster and breast cancer survivor Peggy Fleming will be the celebrity host at the National Constitution Center in Philadelphia.

The event will host an expected 500 guests, bringing together pharmaceutical executives and scientists with celebrities and philanthropists. Proceeds support the AACR Foundation's Fund for Translational Cancer Research. Fox Chase Cancer Center is a local partner and beneficiary. For more information, call Fox Chase's institutional advancement office at 215-728-2745.